Department of Gynecology and Gynecologic Oncology, Kliniken Essen-Mitte, Evangelische Huyssens-Stiftung, Henricistrasse 92, 45136 Essen, Germany.
Anticancer Res. 2013 Sep;33(9):3759-63.
Protein tyrosine kinase-7 (PTK7) plays an important role in cancer. Our aim was to evaluate PTK7 in triple-negative breast cancer (TNBC).
PTK7 Expression was assessed by immunohistochemistry (IHC) in 133 patients with TNBC. Expression levels were correlated with clinicopathological features and survival, taking chemotherapy into account.
Positive PTK7 expression was detected in 28.6% of tumors. In the total population, no significant difference was detected in disease-free survival (DFS) or overall survival (OS) related to PTK7 status. However, in patients treated by chemotherapy, patients with PTK7-negative tumors seemed to have better DFS than those with PTK7-positive tumors, particularly for patients treated with only anthracycline-therapy drugs. In patients receiving other chemotherapy regimens, PTK7 status had no significant impact on DFS or OS.
Our results support earlier findings that PTK7 may be associated with resistance to anthracycline-based chemotherapy.
蛋白酪氨酸激酶 7（PTK7）在癌症中发挥着重要作用。我们的目的是评估三阴性乳腺癌（TNBC）中的 PTK7。
采用免疫组织化学（IHC）方法检测了 133 例 TNBC 患者的 PTK7 表达。考虑化疗因素，将表达水平与临床病理特征和生存相关联。
在 28.6%的肿瘤中检测到阳性的 PTK7 表达。在总人群中，PTK7 状态与无病生存率（DFS）或总生存率（OS）无显著相关性。然而，在接受化疗的患者中，PTK7 阴性肿瘤患者的 DFS 似乎优于 PTK7 阳性肿瘤患者，尤其是接受仅蒽环类药物治疗的患者。在接受其他化疗方案的患者中，PTK7 状态对 DFS 或 OS 无显著影响。
我们的结果支持先前的发现，即 PTK7 可能与蒽环类药物化疗耐药有关。
